Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Japan Pharma Market Expected to Log -0.8% to +0.2% Growth through FY2026: IQVIA
October 29, 2021
- Takeda’s H1 Sales Log Two-Digit Growth Driven by Global Brands, FDA Wraps Up Plant Re-Inspection
October 29, 2021
- Takeda to Snap Up UK Cell Therapy Partner GammaDelta
October 29, 2021
- Ono Files Onoact for Pediatric Tachyarrhythmia
October 29, 2021
- Sumitomo Dainippon to Speed Up Development of CNS Blockbuster Hopeful through Otsuka Alliance
October 28, 2021
- Otsuka Collaboration “More Positive” than Solo Even If Profits Shared: Sumitomo Dainippon Chief
October 28, 2021
- Sumitomo Dainippon’s H1 Sales Surge 12.3% on Otsuka Deal
October 28, 2021
- Chugai/TWOCELLS Complete PIII Enrollment for Knee Chondrogenesis Cell Medicine
October 28, 2021
- CNS Alliance with Otsuka Expected to be Long-term: Sumitomo Dainippon Senior Executive
October 28, 2021
- AbbVie Seeks Ulcerous Colitis Indication for Rinvoq in Japan
October 28, 2021
- Nobelpharma Plans Launch of 3 Products in US, China, Europe: R&D Head
October 27, 2021
- Solasia Grants Japan Rights for Darinaparsin to Nippon Kayaku, Ends Deal with Meiji
October 27, 2021
- Daiichi Sankyo, AstraZeneca to Launch PIII of DS-1062/Keytruda Combo
October 27, 2021
- Sun Pharma Japan to Boost Sales Force, Development to Achieve 1.5-Fold Sales Growth by 2025
October 27, 2021
- Oncolys’ Oral COVID-19 Drug Effective in Hamster Model
October 27, 2021
- MSD Seeks Japan Approval for 15-Valent Pneumococcal Vaccine
October 27, 2021
- Extension of Use Patent Term for Remitch Affirmed: Toray
October 27, 2021
- Choseido Revamps Management, Sacks President Harada over GMP Violations
October 26, 2021
- Sanofi, Nichi-Iko to Dissolve Joint Venture at Year-End
October 26, 2021
- KM Biologics Eyes COVID-19 Booster Filing as Early as Spring, Trial Start Slated by Year-End
October 26, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…